Cargando…
Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation
Metastasis is the major cause of treatment failure in anaplastic thyroid carcinoma (ATC) patients. In the preliminary study, we demonstrated that interleukin (IL)-11 expression is positively correlated with distant metastasis in ATC. However, the mechanisms underlying remain largely unknown. Here, w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312338/ https://www.ncbi.nlm.nih.gov/pubmed/27487122 http://dx.doi.org/10.18632/oncotarget.10831 |
_version_ | 1782508187299086336 |
---|---|
author | Zhong, Zhaoming Hu, Zedong Jiang, Yue Sun, Ruimei Chen, Xue Chu, Hongying Zeng, Musheng Sun, Chuanzheng |
author_facet | Zhong, Zhaoming Hu, Zedong Jiang, Yue Sun, Ruimei Chen, Xue Chu, Hongying Zeng, Musheng Sun, Chuanzheng |
author_sort | Zhong, Zhaoming |
collection | PubMed |
description | Metastasis is the major cause of treatment failure in anaplastic thyroid carcinoma (ATC) patients. In the preliminary study, we demonstrated that interleukin (IL)-11 expression is positively correlated with distant metastasis in ATC. However, the mechanisms underlying remain largely unknown. Here, we found that cobalt chloride (a hypoxia mimetic) promoted IL-11 expression via HIF-1α activation. Furthermore, the resultant increase in IL-11 expression significantly induced epithelial-mesenchymal transition (EMT) in ATC cells, accompanied by Akt/GSK3β pathway activation and increased invasive and migratory abilities. Conversely, HIF-1α or IL-11 knockdown, or treating cells with a neutralizing antibody against IL-11, a PI3K inhibitor, or Akt inhibitor V, significantly suppressed the induction of EMT and counteracted the enhancements in invasive and migratory abilities. These results indicate that hypoxia increases IL-11 secretion in ATC cells via HIF-1α induction and that IL-11 then induces EMT in these cells via the PI3K/Akt/GSK3β pathway, ultimately improving their invasive and migratory potential. This study elucidates the prometastatic role played by IL-11 in ATC metastasis and indicates it as a potential target for the treatment of cancer metastasis. However, many questions remain to be explored. |
format | Online Article Text |
id | pubmed-5312338 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-53123382017-03-06 Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation Zhong, Zhaoming Hu, Zedong Jiang, Yue Sun, Ruimei Chen, Xue Chu, Hongying Zeng, Musheng Sun, Chuanzheng Oncotarget Research Paper Metastasis is the major cause of treatment failure in anaplastic thyroid carcinoma (ATC) patients. In the preliminary study, we demonstrated that interleukin (IL)-11 expression is positively correlated with distant metastasis in ATC. However, the mechanisms underlying remain largely unknown. Here, we found that cobalt chloride (a hypoxia mimetic) promoted IL-11 expression via HIF-1α activation. Furthermore, the resultant increase in IL-11 expression significantly induced epithelial-mesenchymal transition (EMT) in ATC cells, accompanied by Akt/GSK3β pathway activation and increased invasive and migratory abilities. Conversely, HIF-1α or IL-11 knockdown, or treating cells with a neutralizing antibody against IL-11, a PI3K inhibitor, or Akt inhibitor V, significantly suppressed the induction of EMT and counteracted the enhancements in invasive and migratory abilities. These results indicate that hypoxia increases IL-11 secretion in ATC cells via HIF-1α induction and that IL-11 then induces EMT in these cells via the PI3K/Akt/GSK3β pathway, ultimately improving their invasive and migratory potential. This study elucidates the prometastatic role played by IL-11 in ATC metastasis and indicates it as a potential target for the treatment of cancer metastasis. However, many questions remain to be explored. Impact Journals LLC 2016-07-25 /pmc/articles/PMC5312338/ /pubmed/27487122 http://dx.doi.org/10.18632/oncotarget.10831 Text en Copyright: © 2016 Zhong et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Zhong, Zhaoming Hu, Zedong Jiang, Yue Sun, Ruimei Chen, Xue Chu, Hongying Zeng, Musheng Sun, Chuanzheng Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation |
title | Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation |
title_full | Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation |
title_fullStr | Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation |
title_full_unstemmed | Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation |
title_short | Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation |
title_sort | interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through pi3k/akt/gsk3β signaling pathway activation |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312338/ https://www.ncbi.nlm.nih.gov/pubmed/27487122 http://dx.doi.org/10.18632/oncotarget.10831 |
work_keys_str_mv | AT zhongzhaoming interleukin11promotesepithelialmesenchymaltransitioninanaplasticthyroidcarcinomacellsthroughpi3kaktgsk3bsignalingpathwayactivation AT huzedong interleukin11promotesepithelialmesenchymaltransitioninanaplasticthyroidcarcinomacellsthroughpi3kaktgsk3bsignalingpathwayactivation AT jiangyue interleukin11promotesepithelialmesenchymaltransitioninanaplasticthyroidcarcinomacellsthroughpi3kaktgsk3bsignalingpathwayactivation AT sunruimei interleukin11promotesepithelialmesenchymaltransitioninanaplasticthyroidcarcinomacellsthroughpi3kaktgsk3bsignalingpathwayactivation AT chenxue interleukin11promotesepithelialmesenchymaltransitioninanaplasticthyroidcarcinomacellsthroughpi3kaktgsk3bsignalingpathwayactivation AT chuhongying interleukin11promotesepithelialmesenchymaltransitioninanaplasticthyroidcarcinomacellsthroughpi3kaktgsk3bsignalingpathwayactivation AT zengmusheng interleukin11promotesepithelialmesenchymaltransitioninanaplasticthyroidcarcinomacellsthroughpi3kaktgsk3bsignalingpathwayactivation AT sunchuanzheng interleukin11promotesepithelialmesenchymaltransitioninanaplasticthyroidcarcinomacellsthroughpi3kaktgsk3bsignalingpathwayactivation |